Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Opus Genetics (IRD) Return on Capital Employed (2020 - 2026)

Opus Genetics has reported Return on Capital Employed over the past 7 years, most recently at 87.51% for Q1 2026.

  • Quarterly Return on Capital Employed rose 26453.0% to 87.51% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 87.51% through Mar 2026, up 26453.0% year-over-year, with the annual reading at 107.9% for FY2025, 7408.0% up from the prior year.
  • Return on Capital Employed was 87.51% for Q1 2026 at Opus Genetics, up from 109.03% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 64.73% in Q3 2023 and troughed at 784.63% in Q3 2025.
  • The 5-year median for Return on Capital Employed is 87.51% (2026), against an average of 129.66%.
  • Year-over-year, Return on Capital Employed plummeted -70393bps in 2025 and then skyrocketed 26453bps in 2026.
  • A 5-year view of Return on Capital Employed shows it stood at 62.79% in 2022, then crashed by -134bps to 21.11% in 2023, then plummeted by -976bps to 227.12% in 2024, then soared by 52bps to 109.03% in 2025, then rose by 20bps to 87.51% in 2026.
  • Per Business Quant, the three most recent readings for IRD's Return on Capital Employed are 87.51% (Q1 2026), 109.03% (Q4 2025), and 784.63% (Q3 2025).